110 related articles for article (PubMed ID: 15732532)
1. Adjuvanticity of anti-cD40 in vaccine development.
Cairing J; Barr T; Heath AW
Curr Opin Mol Ther; 2005 Feb; 7(1):73-7. PubMed ID: 15732532
[TBL] [Abstract][Full Text] [Related]
2. Modulating vaccine responses with dendritic cells and Toll-like receptors.
Pulendran B
Immunol Rev; 2004 Jun; 199():227-50. PubMed ID: 15233738
[TBL] [Abstract][Full Text] [Related]
3. Targeting split vaccines to the endosome improves vaccination.
Wagner H; Heit A; Schmitz F; Bauer S
Curr Opin Biotechnol; 2004 Dec; 15(6):538-42. PubMed ID: 15560980
[TBL] [Abstract][Full Text] [Related]
4. New horizons in adjuvants for vaccine development.
Reed SG; Bertholet S; Coler RN; Friede M
Trends Immunol; 2009 Jan; 30(1):23-32. PubMed ID: 19059004
[TBL] [Abstract][Full Text] [Related]
5. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
Weeratna RD; Makinen SR; McCluskie MJ; Davis HL
Vaccine; 2005 Nov; 23(45):5263-70. PubMed ID: 16081189
[TBL] [Abstract][Full Text] [Related]
6. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
[TBL] [Abstract][Full Text] [Related]
7. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists.
Welters MJ; Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH
Vaccine; 2007 Feb; 25(8):1379-89. PubMed ID: 17123670
[TBL] [Abstract][Full Text] [Related]
8. The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity.
Marshak-Rothstein A; Busconi L; Rifkin IR; Viglianti GA
Rheum Dis Clin North Am; 2004 Aug; 30(3):559-74, ix. PubMed ID: 15261341
[TBL] [Abstract][Full Text] [Related]
9. CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the CD40 signal to B cells, but does not substitute for T cell help in responses to TD antigens.
Barr TA; Carlring J; Heath AW
Vaccine; 2005 May; 23(26):3477-82. PubMed ID: 15837371
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
11. Vaccines: exploiting the role of toll-like receptors.
Koganty RR
Expert Rev Vaccines; 2002 Aug; 1(2):123-4. PubMed ID: 12901548
[No Abstract] [Full Text] [Related]
12. Taking a toll road to better vaccines.
Morley SC; Allen PM
Immunity; 2008 May; 28(5):602-4. PubMed ID: 18482564
[TBL] [Abstract][Full Text] [Related]
13. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
14. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
Evans JT; Cluff CW; Johnson DA; Lacy MJ; Persing DH; Baldridge JR
Expert Rev Vaccines; 2003 Apr; 2(2):219-29. PubMed ID: 12899573
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin M as a vaccine adjuvant.
Ilag LL
Med Hypotheses; 2011 Oct; 77(4):473-8. PubMed ID: 21723670
[TBL] [Abstract][Full Text] [Related]
17. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
18. Smart adjuvants.
Schmidt CS; Morrow WJ; Sheikh NA
Expert Rev Vaccines; 2007 Jun; 6(3):391-400. PubMed ID: 17542754
[TBL] [Abstract][Full Text] [Related]
19. Evolution and integration of innate immune recognition systems: the Toll-like receptors.
Takeda K
J Endotoxin Res; 2005; 11(1):51-5. PubMed ID: 15826379
[TBL] [Abstract][Full Text] [Related]
20. The perfect mix: recent progress in adjuvant research.
Guy B
Nat Rev Microbiol; 2007 Jul; 5(7):505-17. PubMed ID: 17558426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
